LIFEVANTAGE CORP Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
LIFEVANTAGE CORP (LFVN) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $200.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2026-08-27
- LIFEVANTAGE CORP effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2026 was $200.00K, a 75.00% decline from fiscal 2025.
- LIFEVANTAGE CORP effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2025 was $800.00K, a 300.00% increase from fiscal 2024.
- LIFEVANTAGE CORP effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was $200.00K, a 0.00% change from fiscal 2023.
- LIFEVANTAGE CORP effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2023 was $200.00K, a 0.00% change from fiscal 2022.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2026-06-30 | $200.00K 10-K · filed 2026-08-27 |
| 2025-06-30 | $800.00K 10-K · filed 2026-08-27 |
| 2024-06-30 | $200.00K 10-K · filed 2025-09-04 |
| 2023-06-30 | $200.00K 10-K · filed 2024-08-28 |
| 2022-06-30 | $200.00K 10-K · filed 2023-08-28 |
| 2021-06-30 | $8.00K 10-K · filed 2022-08-23 |
| 2020-06-30 | $2.00M 10-K · filed 2021-08-19 |
| 2019-06-30 | -$700.00K 10-K · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |